Safety Study of MGA271 in Refractory Cancer

Clinical Trial ID NCT01391143

Rank	Title	Journal	Year	PubWeight™‹?›
1	Immune checkpoint blockade: a common denominator approach to cancer therapy.	Cancer Cell	2015	5.10
2	Immune checkpoint inhibitors in clinical trials.	Chin J Cancer	2014	0.98
3	From bench to bedside a comprehensive review of pancreatic cancer immunotherapy.	J Immunother Cancer	2016	0.90
4	Blocking immune checkpoints in prostate, kidney, and urothelial cancer: An overview.	Urol Oncol	2016	0.86
5	T cell coinhibition and immunotherapy in human breast cancer.	Discov Med	2012	0.85
6	Decreased expression of B7-H3 reduces the glycolytic capacity and sensitizes breast cancer cells to AKT/mTOR inhibitors.	Oncotarget	2016	0.83
7	Fueling the engine and releasing the break: combinational therapy of cancer vaccines and immune checkpoint inhibitors.	Cancer Biol Med	2015	0.80
8	Inhibiting Immune Checkpoints for the Treatment of Bladder Cancer.	Bladder Cancer	2016	0.79
9	Immunobiology and immunotherapy in genitourinary malignancies.	Ann Transl Med	2016	0.78
10	New Strategies in Bladder Cancer: A Second Coming for Immunotherapy.	Clin Cancer Res	2015	0.78
11	Immune checkpoint blockade therapy for bladder cancer treatment.	Investig Clin Urol	2016	0.78
12	Molecular Pathways: Targeting B7-H3 (CD276) for Human Cancer Immunotherapy.	Clin Cancer Res	2016	0.76